Put Options

8 transactions
Quarter Operation Price Per put puts change puts Held SEC Form
Q2 2024

Aug 14, 2024

BUY
$3.04 - $4.23 $18,848 - $26,226
6,200 Added 7.87%
85,000 $345,000
Q1 2024

May 15, 2024

BUY
$2.88 - $4.89 $41,184 - $69,927
14,300 Added 22.17%
78,800 $271,000
Q4 2023

Feb 14, 2024

SELL
$1.08 - $3.63 $18,684 - $62,799
-17,300 Reduced 21.15%
64,500 $210,000
Q3 2023

Nov 14, 2023

BUY
$2.81 - $5.69 $129,541 - $262,309
46,100 Added 129.13%
81,800 $238,000
Q2 2023

Aug 14, 2023

SELL
$4.45 - $7.57 $7,565 - $12,869
-1,700 Reduced 4.55%
35,700 $194,000
Q1 2023

May 15, 2023

SELL
$2.48 - $5.22 $156,488 - $329,382
-63,100 Reduced 62.79%
37,400 $173,000
Q4 2022

Feb 14, 2023

SELL
$1.75 - $3.96 $114,625 - $259,380
-65,500 Reduced 39.46%
100,500 $227,000
Q3 2022

Nov 14, 2022

BUY
$3.09 - $7.46 $235,149 - $567,706
76,100 Added 84.65%
166,000 $523,000

Others Institutions Holding OMER

About OMEROS CORP


  • Ticker OMER
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 62,730,000
  • Market Cap $248M
  • Description
  • Omeros Corporation, a commercial-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting inflammation, complement-mediated diseases, cancers related to dysfunction of the immune system, and addictive and compulsive disorders. The company's clinical program...
More about OMER
Track Ken Griffin's Portfolio

Track Ken Griffin Portfolio

Follow Ken Griffin (Citadel Advisors LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.